HomeCompareKKPCF vs KMB

KKPCF vs KMB: Dividend Comparison 2026

KKPCF yields 5.04% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KKPCF wins by $21.2K in total portfolio value
10 years
KKPCF
KKPCF
● Live price
5.04%
Share price
$26.00
Annual div
$1.31
5Y div CAGR
25.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$67.1K
Annual income
$13,096.91
Full KKPCF calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — KKPCF vs KMB

📍 KKPCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKKPCFKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KKPCF + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KKPCF pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KKPCF
Annual income on $10K today (after 15% tax)
$428.27/yr
After 10yr DRIP, annual income (after tax)
$11,132.37/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, KKPCF beats the other by $6,693.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KKPCF + KMB for your $10,000?

KKPCF: 50%KMB: 50%
100% KMB50/50100% KKPCF
Portfolio after 10yr
$56.5K
Annual income
$9,159.62/yr
Blended yield
16.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

KKPCF
No analyst data
Altman Z
4.9
Piotroski
2/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KKPCF buys
0
KMB buys
0
No recent congressional trades found for KKPCF or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKKPCFKMB
Forward yield5.04%5.25%
Annual dividend / share$1.31$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR25.2%17%
Portfolio after 10y$67.1K$45.9K
Annual income after 10y$13,096.91$5,222.34
Total dividends collected$40.8K$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: KKPCF vs KMB ($10,000, DRIP)

YearKKPCF PortfolioKKPCF Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$11,331$630.82$11,314$614.45+$17.00KKPCF
2$12,960$836.34$12,867$760.19+$93.00KKPCF
3$14,987$1,119.33$14,713$945.27+$274.00KKPCF
4$17,550$1,514.52$16,924$1,181.90+$626.00KKPCF
5$20,854$2,075.26$19,596$1,486.64+$1.3KKKPCF
6$25,199$2,885.36$22,850$1,882.16+$2.3KKKPCF
7$31,043$4,079.59$26,849$2,399.80+$4.2KKKPCF
8$39,096$5,880.43$31,812$3,083.36+$7.3KKKPCF
9$50,499$8,665.70$38,033$3,994.72+$12.5KKKPCF
10$67,131$13,096.91$45,918$5,222.34+$21.2KKKPCF

KKPCF vs KMB: Complete Analysis 2026

KKPCFStock

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

Full KKPCF Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this KKPCF vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KKPCF vs SCHDKKPCF vs JEPIKKPCF vs OKKPCF vs KOKKPCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.